Vytorin Headache Grows With Shareholder Suit
In the wake of the Vytorin controversy, a proposed class action is accusing Merck & Co. and its leaders of deliberately trying to mislead shareholders over the cholesterol drug in order...To view the full article, register now.
Already a subscriber? Click here to view full article